Drug eluting medical device
The present disclosure relates to medical devices, and methods for producing and using the devices. In embodiments, the medical device may be a buttress including a porous substrate possessing a therapeutic layer of a chemotherapeutic agent and optional excipient(s) thereon. By varying the form of chemotherapeutic agents and excipients, the medical devices may be used to treat both the area to which the medical device is attached as well as tissue at a distance therefrom.
1. A medical device comprising:
a porous buttress; and
a therapeutic layer on at least a portion of the porous buttress, the therapeutic layer including a chemotherapeutic agent in combination with an excipient selected from the group consisting of 2-hydroxypropyl-beta-cyclodextrin, methyl-β-cyclodextrin, sodium dodecyl sulfate, octylglucoside, sorbitan monooleate, sorbitan monolaurate, polyethoxylated fatty acid esters of sorbitan, oleic acid, citric acid, ascorbic acid, butylated hydroxytoluene, D-sorbitol, and combinations thereof,
wherein the therapeutic layer has a surface to volume ratio from about 500 mm −1 to about 90,000 mm −1 .
2. The medical device of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of paclitaxel and derivatives thereof, docetaxel and derivatives thereof, abraxane, tamoxifen, cyclophosphamide, actinomycin, bleomycin, dactinomycin, daunorubicin, doxorubicin, doxorubicin hydrochloride, epirubicin, mitomycin, methotrexate, fluorouracil, gemcitabine, gemcitabine hydrochloride, carboplatin, carmustine, methyl-CCNU, cisplatin, etoposide, camptothecin and derivatives thereof, phenesterine, vinblastine, vincristine, goserelin, leuprolide, interferon alfa, retinoic acid, nitrogen mustard alkylating agents, piposulfan, vinorelbine, irinotecan, irinotecan hydrochloride, vinblastine, pemetrexed, sorafenib tosylate, everolimus, erlotinib hydrochloride, sunitinib malate, capecitabine oxaliplatin, leucovorin calcium, bevacizumab, cetuximab, ramucirumab, trastuzumab, and combinations thereof.
3. The medical device of claim 1 , wherein the chemotherapeutic agent includes a polymorph of paclitaxel.
4. The medical device of claim 3 , wherein the polymorph of paclitaxel is selected from the group consisting of amorphous paclitaxel, crystalline paclitaxel dihydrate, anhydrous paclitaxel, and combinations thereof.
5. The medical device of claim 3 , wherein the paclitaxel is a combination of amorphous paclitaxel and crystalline paclitaxel dihydrate.
6. The medical device of claim 5 , wherein the amorphous paclitaxel is released from the medical device over a period of time from about 24 hours to about 168 hours, and the crystalline paclitaxel dihydrate is released from the medical device over a period of time from about 1 week to about 6 weeks.
7. The medical device of claim 1 , wherein the excipient is selected from the group consisting of methyl-β-cyclodextrin, oleic acid, polysorbate 80, D-sorbitol, octylglucoside, and combinations thereof.
8. The medical device of claim 1 , wherein the porous buttress has a pore volume from about 65% to about 85%.
9. A method for treating tissue comprising applying the medical device of claim 1 to tissue.
10. The method of claim 9 , wherein applying the medical device to tissue occurs with a fixation device selected from the group consisting of staples, tacks, clips, sutures, adhesives, and combinations thereof.
11. A medical device comprising:
a porous buttress; and
a therapeutic layer on at least a portion of the porous buttress, the therapeutic layer including amorphous paclitaxel and crystalline paclitaxel dihydrate in combination with an excipient selected from the group consisting of methyl-β-cyclodextrin, oleic acid, polysorbate 80, D-sorbitol, octylglucoside, and combinations thereof,
wherein the therapeutic layer has a surface to volume ratio from about 500 mm −1 to about 90,000 mm −1 .
12. The medical device of claim 11 , wherein the amorphous paclitaxel is released from the medical device over a period of time from about 24 hours to about 168 hours, and the crystalline paclitaxel dihydrate is released from the medical device over a period of time from about 1 week to about 6 weeks.
13. The medical device of claim 11 , wherein the excipient is present in an amount from about 0.014% to about 14% by weight of the coated buttress.
14. The medical device of claim 11 , wherein the amorphous paclitaxel and crystalline paclitaxel dihydrate are present in an amount from about 0.1% to about 50% by weight of the coated buttress.
15. The medical device of claim 11 , wherein the medical device has a pore volume from about 65% to about 85%.
16. A method for treating tissue comprising applying the medical device of claim 11 to tissue.
17. The method of claim 16 , wherein applying the medical device to tissue occurs with a fixation device selected from the group consisting of staples, tacks, clips, adhesives, sutures, and combinations thereof.
18. A method of treating cancer, comprising:
introducing to a patient a surgical stapler having the medical device of claim 1 thereon; and
using the stapler to remove an undesired portion of an organ and emplace the medical device in a remaining portion of the organ, including stapling the medical device to tissue and cutting the tissue.
19. The method according to claim 18 , wherein the stapler is used on the lung, and/or the medical device is made from a non-woven material.